Alisertib (MLN8237)

Catalog No.S1133

Alisertib (MLN8237) Chemical Structure

Molecular Weight(MW): 518.92

Alisertib (MLN8237) is a selective Aurora A inhibitor with IC50 of 1.2 nM in a cell-free assay. It has >200-fold higher selectivity for Aurora A than Aurora B. Phase 3.

Size Price Stock Quantity  
In DMSO USD 168 In stock
USD 120 In stock
USD 210 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 48 Publications

12 Customer Reviews

  • Inhibition of Aurka kinase activity by MLN8237 impairs expression of pluripotency genes in CCE cells as measured by qRT-PCR. All values shown are mean ?SEM for n=3. The level of phosphorylated H3(S10) (p-H3(S10)), an Aurka phosphorylation target site, is decreased in MLN8237-treated samples.

    Cell Stem Cell 2012 11, 179-94. Alisertib (MLN8237) purchased from Selleck.

    Recruitment of clathrin to the mitotic spindle is controlled by phosphorylation of TACC3 by Aurora-A kinase. Representative micrographs of HEK293 cells incubated with 0.3 μM MLN8237 for 40 min. Cells were fixed and stained as indicated.

    EMBO J 2012 30, 906-19. Alisertib (MLN8237) purchased from Selleck.

  • Aurora A inhibition rescues the PPP6C depletion phenotype. (A) HeLa cells transfected for 48 h with control and PPP6C si08 duplexes were treated with 10 or 20 nM MLN8237 or a solvent control for 15 min before lysis in phosphatase inhibitor containing buffer or fixation. Total lysates were analyzed by Western blotting. The red and black lines indicate the hosphorylated and nonphosphorylated forms of Aurora A. Fixed cells were stained using DAPI to detect DNA and antibodies to α-tubulin and Aurora A pT288. The intensity of pT288 staining was integrated using ImageJ over the spindle region defined by TPX2 staining and is plotted in the bar graph ( n = 4). Arrowheads indicate micronuclei. Bar, 5 µm. (B) HeLa cells transfected for 48 h with control and PPP6C si08 duplexes were treated with 10 nM MLN8237 or a solvent control for 24 h before fixation and staining with DAPI to detect DNA.

    J Cell Biol 2010 191, 1315-32. Alisertib (MLN8237) purchased from Selleck.

    NUSAP mitotic phosphorylation at Ser 240 correlates with Aurora A activity. Protein samples of FLAG-NUSAP immunoprecipitated from I, M and MtMLN or with MtZM were analysed using LC-MS/MS, focusing on the predicted phosphorylated residue Ser 240. The histograms (A, B) show the calculated ratios based on peptides carrying the phosphorylated Ser 240 compared with all matched peptides containing this residue.

     

     

    EMBO reports 2010 11, 977-984. Alisertib (MLN8237) purchased from Selleck.

  • D) Pharmacological inhibition of AURKA using alisertib led to downregulation of p-EIF4E (S209) and c-MYC proteins in FLO-1 and SK-GT-4 resistant cells, with or without RAD001 treatment.

    Clin Cancer Res, 2017, 23(14):3756-3768. Alisertib (MLN8237) purchased from Selleck.

    Tissue levels of 53BP1, a-tubulin, IkB-a and IL-6 in an Hs294T xenograft treated with MLN8237 or vehicle control were visualized by immunofluorescence co-staining with DAPI. Representative micrographs are shown from triplicate experiments.

    EMBO Mol Med 2013 5(1), 149-66. Alisertib (MLN8237) purchased from Selleck.

  • Alisertib inhibits AURKA and AURKB in a concentration-dependent manner. (a) Alisertib induces G 2 /M delay or genome reduplication. HeLa cells were exposed to buffer or the indicated concentrations of Alisertib. After 24 h, the cells were harvested and analyzed with flow cytometry. The positions of 2N, 4N and 8N DNA contents are indicated. (b) Alisertib delays mitotic exit or induces slippage. HeLa cells stably expressing histone H2B-GFP were exposed to buffer or the indicated concentrations of Alisertib. Individual cells were then tracked for 24 h with time-lapse microscopy. Each horizontal bar represents one cell (n ¼ 50). Key: light gray ¼ interphase; black ¼ mitosis (from DNA condensation to anaphase or mitotic slippage); dark gray ¼ interphase after mitotic slippage; truncated bars ¼ cell death. (c) Different concentrations of Alisertib are involved in delaying mitotic exit and inducing slippage. Live-cell imaging of cells treated with Alisertib was described in panel (b). The duration of mitosis (mean±90% confidence interval) and the percentage of cells that underwent mitotic slippage during the imaging period was quantified. (d) Alisertib promotes apoptosis in a concentration-dependent manner. HeLa cells were incubated with the indicated concentrations of Alisertib for 48 h. The cells were then harvested and analyzed with flow cytometry. (e) Concentration-dependent cytotoxicity of Alisertib. HeLa cells were cultured in the presence of the indicated concentrations of Alisertib for 48 h. The number of live and dead cells was analyzed with trypan blue exclusion assay. (f) Concentration-dependent suppression of long-term survival by Alisertib. HeLa cells were seeded on 60-mm culture plates and grown in the presence of 250 n M or 1 m M of Alisertib. After 24 h, the cells were washed gently and propagated in normal medium for another 10–12 days. Colonies were fixed and stained with crystal violet solution (examples of the plates are shown). Average±s.d. from three independent experiments. (g) Both AURKA and AURKB are inhibited by Alisertib.Mitotic HeLa cells were obtained by exposure to nocodazole for 16 h followed by mechanical shake off. The cells were incubated with the indicated concentrations of Alisertib for 2 h. Lysates were then prepared and activated phospho-AURKAThr288 and AURKBThr232were detected with immunoblotting. The asterisk indicates the position of an AURKB-like protein (the same throughout this study). Uniform loading was confirmed by immunoblotting for actin. In this assay, nocodazole and MG132 (a proteasome inhibitor) were added to prevent the cells from exiting mitosis. Accordingly, the total AURKA and AURKB levels remained constant throughout the experiment. (h) Alisertib prevents activation of AURKA and AURKB. HeLa cells were incubated with the indicated concentrations of Alisertib for 8 h. Nocodazole was then added for another 6 h to trap cells that entered mitosis. Lysates were prepared and analyzed with immunoblotting. Actin analysis was included to assess loading and transfer.

    Oncogene 2014 33, 3550-60. Alisertib (MLN8237) purchased from Selleck.

    Inhibition of Aurora A (12.5 nM) by MLN8054 or MLN8237 was assessed in duplicate radiometric assays containing 100 μM [γ-32P] ATP and quantified by p81 phosphocellulose assay and scintillation counting. Kinase activity is reported as a percentage of control calculated from duplicate incubations containing 2.5% (v/v) DMSO. IC50 values represent the mean ±SEM calculated from two independent experiments.

     

     

    ACS Chem Biol 2010 5, 563-576. Alisertib (MLN8237) purchased from Selleck.

  • The effects of T217D and T217N Aurora A mutations were directly compared to WT Aurora A-expressing cells. Each well was treated with either DMSO or 500 nM MLN8054 (E), or 30 nM MLN8237 (F) on day one of the experiment and cells were cultured for 8 days, at which point they were fixed. For all colony assays, an area encompassing >90 % of the colonies per dish is shown. Similar results were seen in two independent duplicate experiments.

    ACS Chem Biol 2010 5, 563-576. Alisertib (MLN8237) purchased from Selleck.

    C, Fry depletion decreases the level of Thr-210 phosphorylation of Plk1 on spindle poles. HeLa cells transfected with siRNAs were cultured in growth medium for 12 h and in thymidine-containing medium for 36 h. They were then released from thymidine arrest for 12 h before being fixed and stained with anti-Plk1 pT210 ( green) and anti-pericentrin (red) antibodies. DNA was stained with TO-PRO-3 ( blue ). For Aurora A inhibition, after release from thymidine block for 10 h, HeLa cells transfected with control siRNA were incubated for2h in medium containing MLN8237 (100 nM) and MG132 (10 μM). Magnified images of the white boxes are also shown. Scale bar ,5 μm.

    J Biol Chem 2012 287, 27670-81. Alisertib (MLN8237) purchased from Selleck.

  • B, drug-treated cells were also stained with DAPI to visualize nuclear DNA and analyzed with a microscope equipped with a fluorescence digital CCD camera. Representative results are shown. Bar, 40 μm.

    J Biol Chem, 2017, 292(5):1910-1924. Alisertib (MLN8237) purchased from Selleck.

    Eg5 inhibition counteracts the induction of spindle pole fragmentation by Aurora-A inactivation. The protocol to inhibit Aurora-A by MLN8237 in cells progressing towards mitosis is depicted (time intervals not represented to scale). Control cultures were treated with solvent (DMSO) in the same time window. When indicated, MON was added 1 hour before harvesting. Note the absence of active phosphorylated (pThr288) Aurora-A (in red in IF panels) in cells treated with MLN8237. Upper histograms represent the percentage of all spindle and MT abnormalities in control and MLN8237-treated cultures (200 counted PM/M per condition in 2 experiments); the grey fraction of the histograms represents mitoses with spindle extrapoles, while other defects (monopolar or disorganised spindles, few and short MTs) are in white. Lower histograms and IF panels show that concomitant Eg5 inhibition by MON prevents MLN8237-induced spindle pole fragmentation (note the failure of centrosome migration reflecting Eg5 inactivation in lower IF panels). 200 PM/M per condition were counted in 2 experiments. Error bars represent s.d. **: p < 0.001, χ2 test. Red asterisks indicate significant differences with respect to DMSO controls, and black asterisks significant differences between Aurora-Ai mitoses with active or inactive Eg5. Scale bar: 10 μm

    Mol Cancer 2011 10, 131. Alisertib (MLN8237) purchased from Selleck.

Purity & Quality Control

Choose Selective Aurora Kinase Inhibitors

Biological Activity

Description Alisertib (MLN8237) is a selective Aurora A inhibitor with IC50 of 1.2 nM in a cell-free assay. It has >200-fold higher selectivity for Aurora A than Aurora B. Phase 3.
Features First orally available inhibitor of Aurora A.
Targets
Aurora A [1]
(Cell-free assay)
1.2 nM
In vitro

MLN8237 shows >200-fold higher selectivity for Aurora A than the structurally related Aurora B with an IC50 of 396.5 nM, and does not have any significant activity against 205 other kinases. [1] MLN8237 (0.5 μM) treatment inhibits the phosphorylation of Aurora A in MM1.S and OPM1 cells, without affecting the Aurora B mediated histone H3 phosphorylation. MLN8237 significantly inhibits cell proliferation in multiple myeloma (MM) cell lines with IC50 values of 0.003-1.71 μM. MLN8237 displays more potent anti-proliferation activity against primary MM cells and MM cell lines in the presence of BM stroma cells, as well as IL-6 and IGF-1 than against MM cells alone. MLN8237 (0.5 μM) induces 2- to 6-fold increase in G2/M phase in primary MM cells and cell lines, as well as significant apoptosis and senescence, involving the up-regulation of p53, p21 and p27, as well as PARP, caspase 3, and caspase 9 cleavage. In addition, MLN8237 shows strong synergistic anti-MM effect with dexamethasone, as well as additive effect with doxorubicin and bortezomib. [2] MLN8237 (0.5 μM) treatment causes the inhibition of colony formation of FLO-1, OE19, and OE33 esophageal adenocarinoma cell lines, and induces a significant increase in the percentage of polyploid cells, and subsequently an increase in the percentage of cells in the sub-G1 phase, which can be further enhanced in combination with cisplatin (2.5 μM), involving the higher induction of TAp73β, PUMA, NOXA, cleaved caspase-3, and cleaved PARP as compared with a single-agent treatment. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HCT116 M3TUOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnz5NE42KM7:TR?= M{DCZ|czKGh? MUTEUXNQ MXLJR|UxRTBwMESg{txO M1zuWlI3OTN4Nki0
LS174T M1vlUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWewMlUh|ryP M1zSN|czKGh? NFPudGZFVVOR M1[ybmlEPTB;MD6wOUDPxE1? NFj5PFAzPjF|Nk[4OC=>
T84 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3KzeVAvPSEQvF2= NYeyU2ZZPzJiaB?= NXXKZZV2TE2VTx?= NX;SNVRVUUN3ME2wMlA6KM7:TR?= MlW4NlYyOzZ4OES=
LS180 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHK0WGoxNjVizszN MknjO|IhcA>? M1;i[GROW09? MUHJR|UxRTFizszN NELYc5IzPjF|Nk[4OC=>
SW948 MoG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmj2NE42KM7:TR?= NXzaVFJNPzJiaB?= MkKxSG1UVw>? MkC4TWM2OD1zIN88US=> MYCyOlE{PjZ6NB?=
HCT15 NEH2WodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV:wMlUh|ryP M2K4VFczKGh? NVqycIc5TE2VTx?= MkPjTWM2ODxyLkSg{txO NUH2d41mOjZzM{[2PFQ>
DLD-1 MmnzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVGwMlUh|ryP M3jxXFczKGh? MWXEUXNQ NX\hfHJbUUN3MEywMlgh|ryP NXLVbo9FOjZzM{[2PFQ>
MIP-101 NIXk[5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTrelQxNjVizszN NVLxVY8{PzJiaB?= MlTzSG1UVw>? MVHJR|UxRTFizszN M13tTlI3OTN4Nki0
SNU1544 MmHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjpNE42KM7:TR?= MYe3NkBp NXnoWZZLTE2VTx?= MYPJR|UxRTFizszN NVjx[GxmOjZzM{[2PFQ>
OCI-Ly10 NF\NOoREgXSxdH;4bYMhSXO|YYm= MU[3NkBp MWrEUXNQ MmLETWM2OD1yLkC1PEDPxE1? NHvMelYzPTh5OEOzNS=>
SU-DHL2 NEnNPHhEgXSxdH;4bYMhSXO|YYm= M33xTVczKGh? MX;EUXNQ NHzjeYVKSzVyPUCuNFEh|ryP M{LhZlI2QDd6M{Ox
OCI-LY7 NX;x[HdpS3m2b4TvfIlkKEG|c3H5 MYq3NkBp MnK2SG1UVw>? MmfXTWM2OD1yLkC4NUDPxE1? MWeyOVg4QDN|MR?=
SU-DHL6 NGfNRW9EgXSxdH;4bYMhSXO|YYm= NWPzeYR6PzJiaB?= MoXCSG1UVw>? NVzIdmhuUUN3ME2wMlQ5OiEQvF2= NVLqOXBuOjV6N{izN|E>
Jeko-1 M1LmcmN6fG:2b4jpZ{BCe3OjeR?= NHzuUXQ4OiCq M36yb2ROW09? NUHpOoFkUUN3ME2wMlAzQSEQvF2= M2DkZ|I2QDd6M{Ox
JVM-2 NHnG[HNEgXSxdH;4bYMhSXO|YYm= MUC3NkBp NULkbHJXTE2VTx?= NWK2ZZg6UUN3ME2wMlAyKM7:TR?= NIS1WYEzPTh5OEOzNS=>
Rec-1 MVvDfZRwfG:6aXOgRZN{[Xl? MnvHO|IhcA>? MlfOSG1UVw>? NH21R3BKSzVyPUCuNFg4KM7:TR?= NITURoYzPTh5OEOzNS=>
Z-138 NXP5emJxS3m2b4TvfIlkKEG|c3H5 MXK3NkBp NW\PcWZiTE2VTx?= M1jaRWlEPTB;MD6wNVMh|ryP NFK5UHozPTh5OEOzNS=>
H9 M2TwWWN6fG:2b4jpZ{BCe3OjeR?= MlnXO|IhcA>? NH7yRYZFVVOR M2f4XWlEPTB;MD62JO69VQ>? NULQTolqOjV6N{izN|E>
HH NVz5RoVHS3m2b4TvfIlkKEG|c3H5 NFPIbng4OiCq M37XdWROW09? NHHHTYpKSzVyPUCuO{DPxE1? MWeyOVg4QDN|MR?=
DND41 NEnVd25EgXSxdH;4bYMhSXO|YYm= M1H4OFczKGh? M4TYfmROW09? NVXhUGQ6UUN3ME2wMlEh|ryP NXqze2lWOjV6N{izN|E>
CCL119 MXLDfZRwfG:6aXOgRZN{[Xl? MUe3NkBp NXvzTm1QTE2VTx?= NHvoOWRKSzVyPUCuNFYzKM7:TR?= M{i1VVI2QDd6M{Ox
J.Cam 1.6 MlGwR5l1d3SxeHnjJGF{e2G7 NYn3XGpRPzJiaB?= MmHhSG1UVw>? NXTZdlVYUUN3ME2wMlExPSEQvF2= MUiyOVg4QDN|MR?=
Sup-T1 NUPKTFdtS3m2b4TvfIlkKEG|c3H5 M1[yeVczKGh? MXXEUXNQ MUjJR|UxRTJwMUSyJO69VQ>? NHfVR3AzPTh5OEOzNS=>
Tib 152 MXrDfZRwfG:6aXOgRZN{[Xl? MV:3NkBp NYjTNGRPTE2VTx?= M1rBdmlEPTB;MD64JO69VQ>? M33pflI2QDd6M{Ox
MCF7 NUTUUoh2TnWwY4Tpc44hSXO|YYm= NW\lcYdXPSEQvF2= NY[5NJpqOjRiaB?= MVXEUXNQ MXfJcoR2[2W|IFeyM20h[XK{ZYP0 NIP4PVEzPTh|NESwNS=>
MDA-MB-231 NVztWFZMTnWwY4Tpc44hSXO|YYm= MW[1JO69VQ>? NH;SO|QzPCCq Mo\iSG1UVw>? MlTvTY5lfWOnczDHN{9OKGG{cnXzeC=> NGWxdowzPTh|NESwNS=>
MCF7 M3q0dWZ2dmO2aX;uJGF{e2G7 NILod2I2KM7:TR?= NYTHS45MOjRiaB?= M2W2TWROW09? MU\E[YNz\WG|ZYOgeIhmKGW6cILld5Nqd25ibHX2[Ywhd2ZiQ1TLNU9ETEN{ MVGyOVg{PDRyMR?=
MCF7 M{jHNGZ2dmO2aX;uJGF{e2G7 MUG1JO69VQ>? Ml\KNlQhcA>? M1PvXGROW09? NV7RfXJFTGWlcnXhd4V{KHSqZTDlfJBz\XO|aX;uJIxmfmWuIH;mJGNFUzJ? MUiyOVg{PDRyMR?=
MCF7 NUW5VVFkTnWwY4Tpc44hSXO|YYm= MmXYOUDPxE1? NIfNeoEzPCCq MknHSG1UVw>? NGm4N2NF\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wxib3[gZ5lkdGmwIFKx M16xS|I2QDN2NECx
MCF7 Mk\OSpVv[3Srb36gRZN{[Xl? MXy1JO69VQ>? NYDkRpl5OjRiaB?= Ml\4SG1UVw>? NF7JUZZKdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wxib3[gdFIyKFejZkGvR4lxOQ>? MWKyOVg{PDRyMR?=
MCF7 NF;zdlRHfW6ldHnvckBCe3OjeR?= Ml;DOUDPxE1? MYOyOEBp NYrZZVRlTE2VTx?= NUDw[INCUW6lcnXhd4V{KHSqZTDlfJBz\XO|aX;uJIxmfmWuIH;mJJAzPyCNaYCx NWrUblJDOjV6M{S0NFE>
MDA-MB-231 NXzIPGg1TnWwY4Tpc44hSXO|YYm= M2LPeFUh|ryP MXiyOEBp MojoSG1UVw>? MXfE[YNz\WG|ZYOgeIhmKGW6cILld5Nqd25ibHX2[Ywhd2ZiQ1TLNU9ETEN{ NV25d|U5OjV6M{S0NFE>
MDA-MB-231 NH3DTlRHfW6ldHnvckBCe3OjeR?= NUTxUm82OSEQvF2= MkTSNlQhcA>? MoqzSG1UVw>? MYfJcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ibHX2[Ywhd2ZiQ1TLNi=> MU[yOVg{PDRyMR?=
MDA-MB-231 NGnO[3RHfW6ldHnvckBCe3OjeR?= NFLTWFc2KM7:TR?= NVO3cJhwOjRiaB?= NX7DcZVGTE2VTx?= NYSzbmRVTGWlcnXhd4V{KHSqZTDlfJBz\XO|aX;uJIxmfmWuIH;mJIN6[2yrbjDCNS=> MViyOVg{PDRyMR?=
MDA-MB-231 NIDQWlZHfW6ldHnvckBCe3OjeR?= NG\DVY02KM7:TR?= Ml3mNlQhcA>? NVP6b5VzTE2VTx?= M{\LRWlv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDs[ZZmdCCxZjDwNlEhX2GoMT;DbZAy MX6yOVg{PDRyMR?=
MDA-MB-231 NEToS5BHfW6ldHnvckBCe3OjeR?= NH\NU3E2KM7:TR?= M4XxflI1KGh? NET0eotFVVOR NIfHRYlKdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wxib3[gdFI4KEurcEG= MlTRNlU5OzR2MEG=
MDA-MB-231 MkXhSpVv[3Srb36gRZN{[Xl? NXjucoM{PSEQvF2= NUS1fZQzOjRiaB?= MWXEUXNQ NYG2S4VKUW6lcnXhd4V{KHSqZTDlfJBz\XO|aX;uJIxmfmWuIH;mJJA2Ow>? MWGyOVg{PDRyMR?=
MCF7 M{L3PWFxd3C2b4Ppd{BCe3OjeR?= NXLyUWtwPSEQvF2= M4XUR|I1KGh? MXzEUXNQ MkCzTY5lfWOnczDhdI9xfG:2aXOg[IVifGh? MnH1NlU5OzR2MEG=
MDA-MB-231 M1nucmFxd3C2b4Ppd{BCe3OjeR?= NVjETJhOPSEQvF2= MlLGNlQhcA>? MmjqSG1UVw>? NYP2Z|JiUW6mdXPld{BieG:ydH;0bYMh\GWjdHi= MlPVNlU5OzR2MEG=
MCF7 MYLGeY5kfGmxbjDBd5NigQ>? M4XpVlEh|ryP NV;DS5VrPzJiaB?= M1zUemROW09? NGn1N2lKdmS3Y3XzJIF2fG:yaHHnbYMh\GWjdHi= M1LLblI2QDN2NECx
MDA-MB-231 M2\6dGZ2dmO2aX;uJGF{e2G7 Mkm3NUDPxE1? NELwU|U4OiCq Mof5SG1UVw>? Mn7zTY5lfWOnczDheZRweGijZ3njJIRm[XSq NH\CNoEzPTh|NESwNS=>
U-2 OS MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYO1NEDPxE1? MXKyOEBp NUTXbWluTE2VTx?= MWPJR|UxRTF4Lk[g{txO M4\EeFI2Pzl{OEGx
MG-63 NHvsNYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{iyUlUxKM7:TR?= M4XuXlI1KGh? NFXhNFJFVVOR Ml\KTWM2OD17LkWg{txO Mni0NlU4QTJ6MUG=
U-2 OS NYHWWmxTSXCxcITvd4l{KEG|c3H5 NGTzUI42KM7:TR?= NEfFXJUzPCCq NXHUdZB3TE2VTx?= M2nEPGlv\HWlZYOgZZBweHSxdHnjJINmdGxiZHXheIg> M3zJelI2Pzl{OEGx
MG-63 M1;JTmFxd3C2b4Ppd{BCe3OjeR?= NVzOfVFNPSEQvF2= NYDCTohyOjRiaB?= MofTSG1UVw>? NGf1OG9KdmS3Y3XzJIFxd3C2b4TpZ{Bk\WyuIHTlZZRp MmTLNlU4QTJ6MUG=
U-2 OS NFzaRZNHfW6ldHnvckBCe3OjeR?= MoO5OUDPxE1? Mk[yNlQhcA>? M3mxVWROW09? MlrXVJJwdW:2ZYOgZZV1d3CqYXfpZ{Bk\WyuIHTlZZRp M{LSU|I2Pzl{OEGx
MG-63 MVHGeY5kfGmxbjDBd5NigQ>? NH;EOmw2KM7:TR?= NIL2flkzPCCq MlnwSG1UVw>? M1HDd3Bzd22xdHXzJIF2fG:yaHHnbYMh[2WubDDk[YF1cA>? NFPvPZUzPTd7MkixNS=>
PANC-1 NIPUWpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYe1NEDPxE1? M17pWlI1KGh? NGTzZ45FVVOR NX7DWYNlUUN3ME23MlEh|ryP MkDNNlU3OzJ{MkW=
BxPC-3 NULIOmhMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\wcGp5PTBizszN NVPvdppuOjRiaB?= MVfEUXNQ NIW2boJKSzVyPU[uPEDPxE1? NXvBPWdwOjV4M{KyNlU>
PANC-1 NVHiSXVuTnWwY4Tpc44hSXO|YYm= NIDwN2g2KM7:TR?= Ml3xNlQhcA>? MXnEUXNQ MUnJcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2IHnuJGczN01icHjhd4U> NXHWOZV7OjV4M{KyNlU>
BxPC-3 MUTGeY5kfGmxbjDBd5NigQ>? NED2eHc2KM7:TR?= MnyzNlQhcA>? NEPKT2dFVVOR NWLqS3ZsUW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeEBqdiCJMj;NJJBp[XOn Mln5NlU3OzJ{MkW=
PANC-1 M4HremZ2dmO2aX;uJGF{e2G7 MkTMOUDPxE1? MUGyOEBp NULlcphpTE2VTx?= MoX4TY5lfWOnczDheZRweGijZ3njJINmdGxiZHXheIg> NGPMbWUzPTZ|MkKyOS=>
BxPC-3 M{DtcWZ2dmO2aX;uJGF{e2G7 M4\ETlUh|ryP NWr2R2F3OjRiaB?= MkXmSG1UVw>? MnvXTY5lfWOnczDheZRweGijZ3njJINmdGxiZHXheIg> MXWyOVY{OjJ{NR?=
SKOV3 NG[0S2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLw[3FDOTByIN88US=> MnOzNlQhcA>? MX;EUXNQ NWfwd3B4UUN3ME2yNE41QCEQvF2= NXWzNpN4OjV4MkS3OVA>
OVCAR4 NVfle3RyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTiNVAxKM7:TR?= NX3ETXJQOjRiaB?= M2TWW2ROW09? MlzzTWM2OD1{Mj6xN{DPxE1? MV6yOVYzPDd3MB?=
SKOV3 NEnnfm9HfW6ldHnvckBCe3OjeR?= MmnSOUDPxE1? MYC3NkBp M4LYdWROW09? MWPJcoR2[2W|IFeyM20h[XK{ZYP0 NXuySIU5OjV4MkS3OVA>
OVCAR4 M4HNZ2Z2dmO2aX;uJGF{e2G7 MmfvOUDPxE1? NF3oOno4OiCq MYfEUXNQ NV3LXYdrUW6mdXPld{BIOi:PIHHydoV{fA>? MYSyOVYzPDd3MB?=
SKOV3 NXzobnFXSXCxcITvd4l{KEG|c3H5 MVW1JO69VQ>? M1P5ZVI1KGh? NVrFSphkTE2VTx?= NIO2cpFKdmS3Y3XzJIFxd3C2b4Ppdy=> MlzpNlU3OjR5NUC=
OVCAR4 NHTIdXlCeG:ydH;zbZMhSXO|YYm= M3HIbFUh|ryP NVfOPVdjOjRiaB?= NEP5UoVFVVOR MUTJcoR2[2W|IHHwc5B1d3Orcx?= M{nGd|I2PjJ2N{Ww
AGS MoTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHlNlUh|ryP MYKyOEBp Ml7qSG1UVw>? M3HtW2lEPTB;MUmuNFkh|ryP NHj3UVkzPTZyOUmyNy=>
NCI-N78 MkPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHBO5hiOjVizszN NV3nSIp7OjRiaB?= M1T2[mROW09? MX;JR|UxRTJ4LkOzJO69VQ>? NIfGdIUzPTZyOUmyNy=>
AGS MniyRZBweHSxc3nzJGF{e2G7 M4HLbFUh|ryP M4PaW|I1KGh? NWfKTmFtTE2VTx?= NETLNXZKdmS3Y3XzJIFxd3C2b4Ppdy=> NU\ldlFzOjV4MEm5NlM>
NCI-N78 Mn7nRZBweHSxc3nzJGF{e2G7 MX61JO69VQ>? NX2yVYhnOjRiaB?= NETmWI9FVVOR Mk\xTY5lfWOnczDhdI9xfG:|aYO= Mo\2NlU3ODl7MkO=
AGS M362dGZ2dmO2aX;uJGF{e2G7 NYLFV454PSEQvF2= NVrKWFFNOjRiaB?= M33U[mROW09? M{PCN2lv\HWlZYOgeIhmKGG3dH;wbIFogQ>? M2fqR|I2PjB7OUKz
NCI-N78 NFzmdWRHfW6ldHnvckBCe3OjeR?= NEPDT4c2KM7:TR?= MVqyOEBp MWjEUXNQ MY\JcoR2[2W|IITo[UBifXSxcHjh[5k> NHvJWIkzPTZyOUmyNy=>
HSC-3 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\YeYdwOSEQvF2= M{nnWlQ5KGh? M4nDcmlEPTB;MD61OEDPxE1? MlPwNlU{PjZzNEO=
GB30 NHT5ZVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\LUFQyKM7:TR?= MXW3JIQ> NI\jc3VFVVOR NHjUUnFKSzVyPUCuNFEyKM7:TR?= NFrwfHMzPTFyNkSyPC=>
GB9 M{\2cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\YcFEh|ryP NH\0epk4KGR? M4PzW2ROW09? MkT5TWM2OD1yLkCyOEDPxE1? NFvBbm0zPTFyNkSyPC=>
GB169 M131e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE[weG4yKM7:TR?= MmXzO{Bl MkHTSG1UVw>? MkTYTWM2OD1yLkCzNkDPxE1? NV\wcldYOjVzME[0Nlg>
T24 MUnGeY5kfGmxbjDBd5NigQ>? NY\XPHBFOSEQvF2= M2TobFQ5KGh? NYLDN3NRTE2VTx?= MlHzTY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dB?= NYLodI1EOjN2MEO2N|M>
RT4 NWHZeVdkTnWwY4Tpc44hSXO|YYm= NGq2PJgyKM7:TR?= M{O4XFQ5KGh? MUXEUXNQ MlztTY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dB?= NHX6XVIzOzRyM{[zNy=>
UM-UC-3 MYLGeY5kfGmxbjDBd5NigQ>? MmTBNUDPxE1? MXy0PEBp M3GyN2ROW09? NVPpZWd4UW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeC=> M2jpUFI{PDB|NkOz
T24 MXHBdI9xfG:|aYOgRZN{[Xl? M33WcFMvOTZizszN MVq5OkBp NHnj[45FVVOR NUTMZ21XUUN3ME2wMlA{ODZizszN M4OxNVI{PDB|NkOz
RT4 MW\BdI9xfG:|aYOgRZN{[Xl? NF3JdFQ{NjF4IN88US=> NH\meXM6PiCq NVXKPXF[TE2VTx?= MUfJR|UxRTBwMUG5PEDPxE1? MkLaNlM1ODN4M{O=
UM-UC-3 NEDKRpJCeG:ydH;zbZMhSXO|YYm= MlzNN{4yPiEQvF2= MX25OkBp NV34T4s3TE2VTx?= MnTnTWM2OD1yLkC0OFkh|ryP Mon5NlM1ODN4M{O=
OVCAR-5 NWLpSlk{TnWwY4Tpc44hSXO|YYm= MYC1NEBvVQ>? M4mxSmlvcGmkaYTzJINmdGxibXnndoF1cW:w MlrPNlM{OzR|Mke=
SKOV3ip2 MV7GeY5kfGmxbjDBd5NigQ>? M37RclUxKG6P MYXJcohq[mm2czDj[YxtKG2rZ4LheIlwdg>? M2WxdlI{OzN2M{K3
S462 NUTD[lV7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUixNFAh|ryP NUPYZWtsPzJiaB?= MXnEUXNQ M1f1PWF1fGWwdXH0[ZMh[2WubDDndo94fGh? MkDaNlM{OjhzMUS=
2884 M4\3OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3mzNVExOCEQvF2= NEDiN4Y4OiCq NWXEcGpTTE2VTx?= NFnpcGpCfHSnboXheIV{KGOnbHyg[5Jwf3Sq M{XyTFI{OzJ6MUG0
2885 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\aNlExOCEQvF2= NGn3bI84OiCq Ml3jSG1UVw>? MmXvRZR1\W63YYTld{Bk\WyuIHfyc5d1cA>? NVHIUolZOjN|MkixNVQ>
CRL-2396 NGD4d5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonhNVAxKM7:TR?= NWH0NVJOf2G2ZYK= NFjJTJBKSzVyPUCuNFkzKM7:TR?= NV3pO4FxOjNzNUO1NlQ>
TIB-48 NInrbFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXX2b2pMOTByIN88US=> Mk[0e4F1\XJ? NWrPXmpIUUN3ME2wMlA5QCEQvF2= MXmyN|E2OzV{NB?=
CRL-2396 NVrJVmhZS3m2b4TvfIlkKEG|c3H5 MVWxJO69VQ>? MnTqOFghcA>? MXf3ZZRmeg>? MWLJcoR2[2W|IHHwc5B1d3Orcx?= NVG5enN3OjNzNUO1NlQ>
TIB-48 NHXqUlJEgXSxdH;4bYMhSXO|YYm= MmHkNUDPxE1? MV[0PEBp M4LFUpdifGW{ MUPJcoR2[2W|IHHwc5B1d3Orcx?= MmHVNlMyPTN3MkS=
AGS M2PNWWN6fG:2b4jpZ{BCe3OjeR?= M{nPTlAvPSEQvF2= NIi2b5czPCCq MkPHSG1UVw>? NHrUN4RF\WO{ZXHz[ZMh[2WubDDzeZJ3cX[jbB?= NVXy[oRxOjJ7N{K2NVE>
FLO-1 Mn\JR5l1d3SxeHnjJGF{e2G7 M4LJfFAvPSEQvF2= MoT2NlQhcA>? MkLoSG1UVw>? MULE[YNz\WG|ZYOgZ4VtdCC|dYL2bZZidA>? MXGyNlk4OjZzMR?=
OE33 MnLCR5l1d3SxeHnjJGF{e2G7 MVewMlUh|ryP NWr1OmhGOjRiaB?= MoD0SG1UVw>? Mmq0SIVkemWjc3XzJINmdGxic4Xyeol3[Wx? NYXGeolrOjJ7N{K2NVE>
SKLMS NWC1RYRuS3m2b4TvfIlkKEG|c3H5 M{HESVc2KG6P NYL6SJExQTZiaB?= MUXJcoR2[2W|IHHwc5B1d3Orcx?= M1jZT|IzQDJzOUm3
Leio285 NGHqbodEgXSxdH;4bYMhSXO|YYm= NYG3fWFEPzVibl2= NYPhNWkzQTZiaB?= NX\wfFNIUW6mdXPld{BieG:ydH;zbZM> MnqwNlI5OjF7OUe=
Mes-Sa MnXhR5l1d3SxeHnjJGF{e2G7 MUe3OUBvVQ>? NWXYPHdLQTZiaB?= MmjoTY5lfWOnczDhdI9xfG:|aYO= MYOyNlgzOTl7Nx?=
DAOY M1zoc2N6fG:2b4jpZ{BCe3OjeR?= MnfjNVAh|ryP NXToNoxOPzJiaB?= NGPVcHlFVVOR NXHKcIpOUUN3ME2wMlA1KM7:TR?= M4TvV|IzPjZ7M{O1
IMR32 NFe4NlBEgXSxdH;4bYMhSXO|YYm= NXv4[I9TOTBizszN MmDLO|IhcA>? M2HBWWROW09? NF\ST4RKSzVyPUCuNFMh|ryP M4C5W|IzPjZ7M{O1
Molt-4 NF2zPHBEgXSxdH;4bYMhSXO|YYm= NV7W[mx{OTBizszN M3\DR|czKGh? NGH4VJpFVVOR NFnmVm1KSzVyPUCuNFIh|ryP NHHaSGkzOjZ4OUOzOS=>
MOLM-13 M3vzcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{W3dlMh|ryP MXS3NkBp MV;EbY1qdmm|aHXzJINmdGxidnnhZoltcXS7 NE\JcVkzOjR6OEK0PS=>
HL-60 M{T2fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVyzJO69VQ>? Mli3O|IhcA>? M1jxUGRqdWmwaYPo[ZMh[2WubDD2bYFjcWyrdIm= NXnq[m85OjJ2OEiyOFk>
MV4-11 NVLPTnBST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjvUHQ{KM7:TR?= MV63NkBp NV3DW412TGmvaX7pd4hmeyClZXzsJJZq[WKrbHn0fS=> NWT4SI9rOjJ2OEiyOFk>
SKM-1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\TfnNFOyEQvF2= NXPFbXZRPzJiaB?= MX7EbY1qdmm|aHXzJINmdGxidnnhZoltcXS7 NF[2R3AzOjR6OEK0PS=>
SH2 NYnlbmExT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfXN{DPxE1? NWqwfYllPzJiaB?= NXftenBQTGmvaX7pd4hmeyClZXzsJJZq[WKrbHn0fS=> MYeyNlQ5QDJ2OR?=
NOMO-1 MnL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHziZ|Q{KM7:TR?= NGr1TGo4OiCq NXnFfm1pTGmvaX7pd4hmeyClZXzsJJZq[WKrbHn0fS=> MXqyNlQ5QDJ2OR?=
OCL-AML2 NHXWWndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTVN{DPxE1? MX23NkBp NF3vTXdFcW2rbnnzbIV{KGOnbHygeoli[mmuaYT5 NUD4d|kxOjJ2OEiyOFk>
PL-21 NFjGUJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUOzJO69VQ>? NWHsRmVlPzJiaB?= NHfkXJZFcW2rbnnzbIV{KGOnbHygeoli[mmuaYT5 MXyyNlQ5QDJ2OR?=
KG-1 MnvYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3T5fFMh|ryP NE\Tb2s4OiCq NHr2VoxFcW2rbnnzbIV{KGOnbHygeoli[mmuaYT5 NF\HWo8zOjR6OEK0PS=>
A172 NVTvXJdWS3m2b4TvfIlkKEG|c3H5 MYWxNFAh|ryP NGXjV5IzPCCq NUL6RWgzTE2VTx?= NIrweYdKSzVyPUCuNVIxKM7:TR?= NXqyS|Y4OjJ{N{SzPVk>
U87 M4XrdmN6fG:2b4jpZ{BCe3OjeR?= MmXUNVAxKM7:TR?= NVHKeZp1OjRiaB?= M{HjPGROW09? NFLPOFJKSzVyPUCuNVA2KM7:TR?= NITi[4ozOjJ5NEO5PS=>
U251 MXLDfZRwfG:6aXOgRZN{[Xl? Mkf5NVAxKM7:TR?= MmTKNlQhcA>? MnKwSG1UVw>? MVXJR|UxRTBwMUCwJO69VQ>? NX2z[JFuOjJ{N{SzPVk>
T98 MYTDfZRwfG:6aXOgRZN{[Xl? NHXzNoQyODBizszN M2LlXFI1KGh? MlGxSG1UVw>? MYLJR|UxRTBwMUK1JO69VQ>? M4rwXlIzOjd2M{m5
LN18 MXXDfZRwfG:6aXOgRZN{[Xl? MkXUNVAxKM7:TR?= NX;INWFMOjRiaB?= NEnUSG1FVVOR MX;JR|UxRTBwMkGwJO69VQ>? NGjHS3MzOjJ5NEO5PS=>
LN443 NWHrbJdOS3m2b4TvfIlkKEG|c3H5 MV6xNFAh|ryP MnXvNlQhcA>? MkXlSG1UVw>? NHy0fmNKSzVyPUCuNlIxKM7:TR?= NYjGPFA6OjJ{N{SzPVk>
HF66 MWfDfZRwfG:6aXOgRZN{[Xl? M17aSlExOCEQvF2= NYP4VXV2OjRiaB?= MVrEUXNQ NVrLeJo2UUN3ME2wMlIzPSEQvF2= M2fsTVIzOjd2M{m5
HF2303 MkD0R5l1d3SxeHnjJGF{e2G7 NUS2S4luOTByIN88US=> NIrlSFQzPCCq NIT1dFFFVVOR NILuVHVKSzVyPUCuNFYxKM7:TR?= NXrVfFdzOjJ{N{SzPVk>
HF2359 NGHrbHlEgXSxdH;4bYMhSXO|YYm= Mk\zNVAxKM7:TR?= MWiyOEBp MmTDSG1UVw>? NE[wZYtKSzVyPUCuNFYxKM7:TR?= NHy3VXIzOjJ5NEO5PS=>
HF2414 MorTR5l1d3SxeHnjJGF{e2G7 MXixNFAh|ryP NFzsd|czPCCq NGe1fGlFVVOR M1jjOGlEPTB;MD6wPFAh|ryP M1iyclIzOjd2M{m5
A-673 MnW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XqXlExKM7:TR?= M2X2Slk3KGh? MXzEUXNQ MUnJR|UxRTBwMEOyJO69VQ>? MmrsNlE1PDh3OUG=
TC-32 MkHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPS[G91OTBizszN NFj6TIU6PiCq M4PDN2ROW09? NHfSeodKSzVyPUCuNFM6KM7:TR?= NIDJdVQzOTR2OEW5NS=>
TC-71 NV7uToN1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXyxNEDPxE1? M3LtWFk3KGh? MX\EUXNQ MULJR|UxRTBwMUCyJO69VQ>? NEHofo4zOTR2OEW5NS=>
SK-N-MC M2PtdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVy3TZN[OTBizszN MYW5OkBp NVjpU5Z6TE2VTx?= NX3MXIFNUUN3ME2wMlA4OiEQvF2= MnHrNlE1PDh3OUG=
CHLA-9 NVS4VmU4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\JNVAh|ryP M4PNS|k3KGh? NHPr[I5FVVOR MYHJR|UxRTBwMEG4JO69VQ>? NITxW2EzOTR2OEW5NS=>
CHLA-10 MmrxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDkNVAh|ryP MVe5OkBp NEPsdnRFVVOR MXnJR|UxRTBwME[wJO69VQ>? NX7sblZvOjF2NEi1PVE>
CHLA-25 M{PWUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPXXlQyOCEQvF2= MVG5OkBp MWfEUXNQ MlrWTWM2OD1yLkG2PEDPxE1? M2jrdFIyPDR6NUmx
CHLA-32 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUGxNEDPxE1? MVe5OkBp MorKSG1UVw>? NFLzZW1KSzVyPUCuNVM3KM7:TR?= NVexRZZxOjF2NEi1PVE>
CHLA-56 NGPCN|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX71XHJXOTBizszN MV[5OkBp MorCSG1UVw>? MVvJR|UxRTFyIN88US=> NXnRW3VDOjF2NEi1PVE>
CHLA-258 NIDROm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvk[3FyOTBizszN M1vXd|k3KGh? NUT5XXBJTE2VTx?= NGXudXJKSzVyPUCuNVMzKM7:TR?= M{ewb|IyPDR6NUmx
COG-E-352 NXfyd3c4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzwWI9EOTBizszN MVu5OkBp MlLqSG1UVw>? MXXJR|UxRTBwMESzJO69VQ>? NVfZVYJHOjF2NEi1PVE>
CHLA-90 M4\s[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjMNVAh|ryP MlHGPVYhcA>? M3S3UWROW09? NGL5ZndKSzVyPUCuNFYyKM7:TR?= NIOxSmUzOTR2OEW5NS=>
CHLA-119 M2n5N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHnRZEyOCEQvF2= Ml3kPVYhcA>? MkjkSG1UVw>? NVTwdFJLUUN3ME2wMlAzOiEQvF2= M4LBNVIyPDR6NUmx
CHLA-122 M1qyeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LBZlExKM7:TR?= MUO5OkBp MmDDSG1UVw>? NYrjZlJFUUN3ME2wMlAyQSEQvF2= M{Pu[lIyPDR6NUmx
CHLA-136 NW\qdHNlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXOfZAyOCEQvF2= MWW5OkBp NYmzeoR[TE2VTx?= NUH3UZAxUUN3ME2wMlA{QSEQvF2= NWjXOHRNOjF2NEi1PVE>
CHLA-140 MoK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVGxNEDPxE1? MUK5OkBp MnXaSG1UVw>? NHTUSGhKSzVyPUCuNFI3KM7:TR?= NH2yc|QzOTR2OEW5NS=>
LA-N-6 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{noUFExKM7:TR?= M2HaNlk3KGh? NX\URZU4TE2VTx?= Mk\rTWM2OD1yLkC1OEDPxE1? M1HrN|IyPDR6NUmx
NB-1643 Mnm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnWNVAh|ryP Mn3QPVYhcA>? Ml7JSG1UVw>? NYHTSVlyUUN3ME2wMlA{PyEQvF2= NVnmU21VOjF2NEi1PVE>
NB-EBc1 NVPzTo1nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVW0bZIyOTBizszN MUG5OkBp MX;EUXNQ NYP3NZhCUUN3ME2wMlA2OCEQvF2= NE\lUWkzOTR2OEW5NS=>
SK-N-BE-1 M3nDUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzKOWoyOCEQvF2= MV25OkBp MV3EUXNQ M3XVeWlEPTB;MD6wNlgh|ryP M3\UUVIyPDR6NUmx
SK-N-BE-2 NV2wO2JwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTiZnRbOTBizszN M3;0T|k3KGh? MnjaSG1UVw>? M4\iWmlEPTB;MD6wN|Yh|ryP M1fnfVIyPDR6NUmx
SMS-KAN NIi0XIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUCxNEDPxE1? NVvCeFRCQTZiaB?= NF:0cllFVVOR NWfn[It1UUN3ME2wMlA{PCEQvF2= NY\WWItnOjF2NEi1PVE>
SMS-KANR MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17lblExKM7:TR?= NXLJTmxqQTZiaB?= MlnWSG1UVw>? M4XFUmlEPTB;MD6wNlYh|ryP M3HVXVIyPDR6NUmx
SMS-KCN NIe2UFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\JUVExKM7:TR?= Ml7kPVYhcA>? MVzEUXNQ MWHJR|UxRTBwMEG5JO69VQ>? NInYXZUzOTR2OEW5NS=>
SMS-KCNR Mk\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnztNVAh|ryP NEXz[Fg6PiCq MUfEUXNQ NHTxeotKSzVyPUCuNFExKM7:TR?= NV24[HVJOjF2NEi1PVE>
SMS-LHN NGO3boVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDhdmsyOCEQvF2= M362flk3KGh? NVn1VY57TE2VTx?= M4Dv[GlEPTB;MD6wN|Ih|ryP NHrtcpEzOTR2OEW5NS=>
SMS-MSN MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vWOVExKM7:TR?= NXjye5ZiQTZiaB?= MlHRSG1UVw>? M4TN[GlEPTB;MD6wNlIh|ryP M3\jNFIyPDR6NUmx
SMS-SAN MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkO2NVAh|ryP NXfJNoJzQTZiaB?= M3XDV2ROW09? MlTUTWM2OD1yLkCyNEDPxE1? M4jaZ|IyPDR6NUmx
Granta-4 NHT5TWFEgXSxdH;4bYMhSXO|YYm= M1G5O|ExKM7:TR?= NYrVSWt{PyCm MYrJR|UxRTBwMESwJO69VQ>? Mn;MNlEzQTF6Nke=
DB NIP3[WhEgXSxdH;4bYMhSXO|YYm= MmDHNVAh|ryP NYXuTJROPyCm NXPESGljUUN3ME2wMlA1OiEQvF2= MUGyNVI6OTh4Nx?=
RL NIrYc3BEgXSxdH;4bYMhSXO|YYm= NHzSOlUyOCEQvF2= NX3xWVdQPyCm MWHJR|UxRTBwMEG1JO69VQ>? M1fEXFIyOjlzOE[3
K562 MorrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrBNVAh|ryP M4\3Nlk3KGh? NIO5fIxKSzVyPUCuNFg4KM7:TR?= M13wVFIyODlzNkOz
LAMA-84 MnnJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\DNVAh|ryP MWW5OkBp NGrpelRKSzVyPUCuNFU4KM7:TR?= NInjXVYzOTB7MU[zNy=>
MM15 Ml7KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7mOW1CPCEQvF2= NV\1UppmPzJiaB?= MYnEUXNQ M2nVTmlEPTB;MD6xN{DPxE1? NIrITG4zODN6Mki0OC=>
OPM1 NFj6SmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXMOEDPxE1? M1H4cVczKGh? MV;EUXNQ M4DQbWlEPTB;MD6wN{DPxE1? MXSyNFM5Ojh2NB?=
RPM1 NV7QTo1NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfXeI81KM7:TR?= NUPRPJJkPzJiaB?= NHPoOIxFVVOR MnHaTWM2OD1zMD6zNkDPxE1? MlrqNlA{QDJ6NES=
INA6 NGXmdHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHW2[3k1KM7:TR?= NXXTU41lPzJiaB?= M{XYNGROW09? MnLxTWM2OD1yLkCwNkDPxE1? NETzUpkzODN6Mki0OC=>
OPM2 NUnBUlZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWi0JO69VQ>? Mkn6O|IhcA>? NVLWWWgyTE2VTx?= NEfpe3BKSzVyPUSuN|ch|ryP NX\vfGl7OjB|OEK4OFQ>
MM1R NFrt[XhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3f3eFQh|ryP NYrYXGpjPzJiaB?= MXvEUXNQ M{XMbmlEPTB;MT62PEDPxE1? NInBUmkzODN6Mki0OC=>
DOX40 MmnoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\LWIc1KM7:TR?= MmrSO|IhcA>? NHLYNZBFVVOR NHnreFRKSzVyPUWuOFgh|ryP MmG3NlA{QDJ6NES=
LR5 NVHpcHVST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rn[lQh|ryP NWPFV3BVPzJiaB?= NHzneXlFVVOR MnywTWM2OD1{LkWzJO69VQ>? NVKy[VFwOjB|OEK4OFQ>
U266 M332fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTHSZN3PCEQvF2= M{W0RlczKGh? MWPEUXNQ Ml\wTWM2OD1zLkSzJO69VQ>? MYSyNFM5Ojh2NB?=
RD MmTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3GyT|ExKM7:TR?= NYDBNoJGQTZiaB?= M3HoeWlEPTB;MD6yNlgh|ryP NEHLfHAzODFyOEOzPC=>
Rh41 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlv5NVAh|ryP NESyR5g6PiCq MX7JR|UxRTBwMEmwJO69VQ>? NV7FZ5I5OjBzMEizN|g>
Rh30 NITadVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXRNVAh|ryP MVq5OkBp NG[0bINKSzVyPUCuNlMxKM7:TR?= NFvYTFAzODFyOEOzPC=>
BT-12 NYPLO3k{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVG1RlU2OTBizszN NV3tWHZkQTZiaB?= M4nWTmlEPTB;MD6wOlAh|ryP MVeyNFExQDN|OB?=
CHLA-266 NIfKN5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnvNHoyOCEQvF2= MkjMPVYhcA>? Mk\FTWM2OD1yLkC3NkDPxE1? M4XRXFIxOTB6M{O4
TC-71 NIPrU|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoC0NVAh|ryP MVi5OkBp NH7WTGpKSzVyPUCuNVAzKM7:TR?= NHzYcFIzODFyOEOzPC=>
SJ-GBM2 MnznS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jFN|ExKM7:TR?= NWOxNHI{QTZiaB?= NF\zdFVKSzVyPUCuNFUxKM7:TR?= MV6yNFExQDN|OB?=
NALM-6 M2HJfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrlS2kyOCEQvF2= MnTJPVYhcA>? M3\ONGlEPTB;MD6wOlIh|ryP NUfVWWs4OjBzMEizN|g>
COG-LL-317 NXvjUZN4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHtW5psOTBizszN NUnabIxuQTZiaB?= MlzRTWM2OD1yLkC0O{DPxE1? NHKzSoUzODFyOEOzPC=>
RS4-11 MmPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUixNEDPxE1? MWq5OkBp M{XzcGlEPTB;MD6wNVgh|ryP MWmyNFExQDN|OB?=
MOLT-4 MoCyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlW4NVAh|ryP M4[2N|k3KGh? MYTJR|UxRTBwMEK2JO69VQ>? MXGyNFExQDN|OB?=
CCRF-CEM NGLmVoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVWxNEDPxE1? M{KyW|k3KGh? NH;B[GlKSzVyPUCuNFk1KM7:TR?= MV6yNFExQDN|OB?=
Kasumi-1 NGjsPHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG[2WJgyOCEQvF2= MoqwPVYhcA>? NWjJ[oV{UUN3ME2wMlExOyEQvF2= MXeyNFExQDN|OB?=
Karpas-299 NIj3WYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPqNVAh|ryP MkTrPVYhcA>? NHHQWHpKSzVyPUCuNFM5KM7:TR?= NUn4WHMzOjBzMEizN|g>
Ramos-RA1 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2Dlb|ExKM7:TR?= NGexU3A6PiCq NFLheVVKSzVyPUCuNVI4KM7:TR?= M{nkV|IxOTB6M{O4

... Click to View More Cell Line Experimental Data

In vivo MLN8237 significantly reduces the tumor burden with tumor growth inhibition (TGI) of 42% and 80% at 15 mg/kg and 30 mg/kg, respectively, and prolongs the survival of mice compared with the control. [2]

Protocol

Kinase Assay:[1]
+ Expand

Aurora A radioactive Flashplate enzyme assay:

Aurora A radioactive Flashplate enzyme assay is conducted to determine the nature and degree of MLN8237-mediated inhibition in vitro. Recombinant Aurora A is expressed in Sf9 cells and purified with GST affinity chromatography. The peptide substrate for Aurora A is conjugated with biotin (Biotin-GLRRASLG). Aurora A kinase (5 nM) is assayed in 50 mM Hepes (pH 7.5), 10 mM MgCl2, 5 mM DTT, 0.05% Tween 20, 2 μM peptide substrate, 3.3 μCi/mL [γ-33P]ATP at 2 μM, and increasing concentrations of MLN8237 by using Image FlashPlates.
Cell Research:[2]
+ Expand
  • Cell lines: MM1.S, MM.1R, LR5, RPMI 8226, DOX40, OPM1, OPM2, INA6, and U266
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 24, 48, and 72 hours
  • Method: Cells are exposed to various concentrations of MLN8237 for 24, 48, and 72 hours. Cells viability is measured using MTT assay, and cell proliferation is measured using 3[H]-thymidine incorporation. For cell cycle analysis, cells are permeabilized by 70% ethanol at -20 °C, and incubated with 50 μg/mL PI and 20 units/mL RNase-A. DNA content is analyzed by flow cytometry using BDFACS-Canto II and FlowJo software. For the detection of apoptosis and senescence, cells are stained with fluorescein isothiocyanate-annexin V and PI. Apoptotic cells are determined by flow cytometric analysis using BDFACS-Canto II and FlowJo software.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Severe combined immune-deficient (SCID) mice inoculated subcutaneously with MM1.S cells
  • Formulation: Formulated in 10% 2-hydroxypropyl-β-cyclodextrin/1% sodium bicarbonate
  • Dosages: ~30 mg/kg/day
  • Administration: Orally
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 27 mg/mL (52.03 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
15% Captisol
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 518.92
Formula

C27H20ClFN4O4

CAS No. 1028486-01-2
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02860000 Not yet recruiting Estrogen Receptor Negative|Estrogen Receptor Positive|HER2/Neu Negative|Postmenopausal|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer Mayo Clinic|National Cancer Institute (NCI) December 2016 Phase 2
NCT02812056 Not yet recruiting Malignant Neoplasms of Digestive Organs|Malignant Neoplasms of Female Genital Organs|Malignant Neoplasms of Lip Oral Cavity and Pharynx|Malignant Neoplasms of Male Genital Organs M.D. Anderson Cancer Center|Millennium Pharmaceuticals, Inc. September 2016 Phase 1
NCT02700022 Recruiting Diffuse Large B-cell Lymphoma|Follicular Lymphoma|Burkitt Lymphoma UNC Lineberger Comprehensive Cancer Center|Millennium Pharmaceuticals, Inc. July 2016 Phase 1
NCT02719691 Recruiting Metastatic Breast Cancer|Solid Tumors University of Colorado, Denver May 2016 Phase 1
NCT02560025 Recruiting Acute Myeloid Leukemia Massachusetts General Hospital|Takeda December 2015 Phase 2
NCT02551055 Active, not recruiting Neoplasms, Advanced or Metastatic Millennium Pharmaceuticals, Inc.|Takeda October 2015 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What is the suggested formulation of this compound for mouse injection(i.p.)?

  • Answer:

    It can be dissolved in 6% DMSO/50% PEG 300/5% Tween 80/ddH2O at 10 mg/ml as a clear solution.

Aurora Kinase Signaling Pathway Map

Aurora Kinase Inhibitors with Unique Features

Related Aurora Kinase Products

Tags: buy Alisertib (MLN8237) | Alisertib (MLN8237) supplier | purchase Alisertib (MLN8237) | Alisertib (MLN8237) cost | Alisertib (MLN8237) manufacturer | order Alisertib (MLN8237) | Alisertib (MLN8237) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID